KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Accumulated Depreciation & Amortization (2016 - 2025)

Teva Pharmaceutical Industries filings provide 17 years of Accumulated Depreciation & Amortization readings, the most recent being $4.7 billion for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 7.19% to $4.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.7 billion, a 7.19% increase, with the full-year FY2025 number at $4.7 billion, up 7.19% from a year prior.
  • Accumulated Depreciation & Amortization hit $4.7 billion in Q4 2025 for Teva Pharmaceutical Industries, up from $4.4 billion in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $5.6 billion in Q4 2023 to a low of $4.4 billion in Q4 2024.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $5.2 billion (2021), compared with a mean of $5.1 billion.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: decreased 21.77% in 2024 and later increased 7.19% in 2025.
  • Teva Pharmaceutical Industries' Accumulated Depreciation & Amortization stood at $5.2 billion in 2021, then grew by 5.29% to $5.5 billion in 2022, then increased by 2.16% to $5.6 billion in 2023, then fell by 21.77% to $4.4 billion in 2024, then increased by 7.19% to $4.7 billion in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $4.7 billion (Q4 2025), $4.4 billion (Q4 2024), and $5.6 billion (Q4 2023) per Business Quant data.